leadf
logo-loader
viewCo-Diagnostics
(
NASDAQ:CODX
)

Co-Diagnostics chief scientific officer to address Bipartisan Commission on Biodefense in Washington

Dr Brent Satterfield invented the CoPrimer tech platform on which the COVID-19 screening test was built

Co-Diagnostics - Co-Diagnostics chief scientific officer to address Bipartisan Commission on Biodefense in Washington
Co-Diagnostics is now shipping its proprietary Logix Smart COVID-19 test to 50 countries across four continents

Co-Diagnostics Inc (NASDAQ:CODX), a molecular diagnostics company with a unique platform for the development of diagnostic tests, revealed Thursday that Dr Brent Satterfield, the company’s co-founder and chief scientific officer, will address a meeting convened by the Bipartisan Commission on Biodefense, in Washington, focused on national biodefense in light of the response to COVID-19.

In a statement, Salt Lake City, Utah-based Co-Diagnostics said the meeting is set for March 18, and will evaluate the response to the coronavirus outbreak and implications for preparedness.

Co-Diagnostics is the first US company to receive a CE-mark for its proprietary COVID-19 diagnostic test. It is currently shipping orders for its test kits to 10-to-12 countries across five continents, including America, Europe, Asia and Australia. It has also had inquiries from nearly 50 countries. The firm’s Logix Smart COVID-19 screening test kits are also making their way to Italy, the most severely impacted country in the European Union.

READ: Co-Diagnostics remains a Buy as its coronavirus test ships to US and international markets: HC Wainwright

The speedy development of the COVID-19 test was made possible by a unique, proprietary design process and patented CoPrimer technology platform that was invented by Dr Satterfield.

In a statement, Dr Satterfield said he would share the details of how the company developed its COVID-19 test so quickly and efficiently with the Bipartisan Commission on Biodefense.

“The company’s proprietary platform serves as a template to develop other tests needed now, and in the future as new pathogens surface in our interconnected world. Our current test detects COVID-19 with a high level of specificity to distinguish it from similar viruses,” said Dr Satterfield.

“However, in addition to recently being declared a pandemic by the World Health Organization, the virus that causes COVID-19 is also believed to be mutating. Co-Diagnostics’ patented CoPrimer technology is uniquely suited to quickly develop multiplex assays that can identify multiple mutations of the virus in a single test when the need arises,” he added.

Capability for rapid development of multiplexed tests

In what is reassuring for the world, Dr Satterfield said the “rapid, efficient development of multiplexed tests is a core competency” of Co-Diagnostics.

Prior to founding Co-Diagnostics in 2013, Dr Satterfield developed new diagnostic platforms for the US Department of Homeland Security, the National Biodefense Analysis and Countermeasures Center, the United States Army Medical Research Institute of Infectious Disease, Sandia National Laboratories, and the California Department of Public Health.

Co-Diagnostics continues to ramp up production to meet surging global demand. It is also seeking emergency use clearance for use as an in vitro diagnostic by the US Food and Drug Administration (FDA) as well as by the CDSCO in India, both of which are expected to further increase the domestic and international reach of the cost-effective diagnostic tool.

Increase in product shipments

The company has been seeing an increase in product shipments of its Logix Smart COVID-19 screening test following the FDA’s decision late last month to allow labs that meet a set of standards known as the Clinical Laboratory Improvement Amendments (CLIA) to use coronavirus detection tests that have been developed and validated before the FDA has reviewed their Emergency Use Authorization (EUA) submission.

Previously, labs seeking to use coronavirus tests had to wait for specific clearance from the FDA. 

In view of the continuing — and rapidly accelerating — COVID-19 infection spread worldwide and initialization of shipments to labs in the US and around the world, investors have snapped up shares of Co-Diagnostics.

The company’s stock was up 18.8% to $15.65 in the pre-market session after the stock nearly doubled when it closed on Wednesday.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive 

Quick facts: Co-Diagnostics

Follow
NASDAQ:CODX

Price: 9.98 USD

Market Cap: $288.32 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Co-Diagnostics to reach wider audience with FDA Emergency Use Authorization...

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan tells Proactive the molecular diagnostics company's Logix Smart coronavirus test has obtained Emergency Use Authorization from the FDA to be used to diagnose SARS-CoV-2. Egan says the authorization confirms the quality and performance of the...

on 04/07/2020

4 min read